Jim Cramer Says 'Hold On' To Palantir, 'Let Them Walk It Up'; Warns That Travere Therapeutics Is Losing A 'Ton Of Money'

On CNBC's “Mad Money Lightning Round,” Jim Cramer said Travere Therapeutics, Inc. TVTX is losing a “ton of money.”

Travere Therapeutics will report third-quarter financial results before the opening bell on Thursday, Oct. 31. Analysts expect the company to report a quarterly loss of 66 cents per share, compared to a year-ago profit of $1.97 per share.

“There is no level that the buyers won't take this stock higher. So I'm going to tell you that I would hold on to it as a spec and let them walk it up,” Cramer said when asked about Palantir Technologies Inc. PLTR.

Palantir Technologies will release results for its third quarter ended Sept. 30, on Monday, Nov. 4, after the closing bell. Analysts expect the company to report quarterly earnings at 9 cents per share, up from 7 cents per share in the year-ago period. The company projects to report revenue of $701.13 million for the quarter.

“I don't think Stanley Black & Decker SWK is going to give you a discouraging forecast,” Cramer said.

On Tuesday, Stanley Black & Decker said its board of directors approved a regular fourth quarter cash dividend of 82 cents per common share. The company also appointed John L. Garrison, Jr, former chairman, president, and chief executive officer of Terex Corporation to its board of directors.

Price Action:

• Palantir shares rose 0.6% to settle at $42.94 on Tuesday.
• Stanley Black & Decker shares fell 0.8% to close at $104.83.
• Travere Therapeutics shares fell 0.7% to settle at $17.97 on Tuesday.

Read Next:

• Top 3 Defensive Stocks That May Keep You Up At Night This Month

Photo: Shutterstock